Literature DB >> 11332575

Intravenous administration of class I antiarrhythmic drugs induced T wave alternans in a patient with Brugada syndrome.

M Chinushi1, T Washizuka, H Okumura, Y Aizawa.   

Abstract

A 71-year-old man who experienced aborted sudden death was referred to our hospital. Coronary artery disease and cerebral accident were ruled out by conventional tests. The 12-lead ECG obtained at rest showed a right bundle branch block pattern and ST segment elevation in leads V1 to V3. Double ventricular extrastimuli at coupling intervals >180 msec induced ventricular fibrillation (VF) twice during electrophysiologic study. Intravenous administration of procainamide accentuated ST segment elevation in leads V1 to V3, and visible T wave alternans was induced in leads V2 and V3 at a dose of 450 mg. Initiation of T wave alternans was not associated with changes of the cardiac cycle or development of premature beats. When procainamide infusion was discontinued, T wave alternans disappeared before the elevated ST segment returned to the control level. Pilsicainide also accentuated ST segment elevation and induced similar T wave alternans in leads V2 and V3. Class I antiarrhythmic drug-related T wave alternans has been reported rarely in Brugada syndrome, but it may represent enhanced arrhythmogenicity of VF. We need to monitor closely and study the clinical implications of T wave alternans in Brugada syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11332575     DOI: 10.1046/j.1540-8167.2001.00493.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  7 in total

1.  Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome.

Authors:  Jeffrey M Fish; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2007-11-21

Review 2.  T-wave alternans: reviewing the clinical performance, understanding limitations, characterizing methodologies.

Authors:  Euler de Vilhena Garcia
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-10       Impact factor: 1.468

3.  Positive Brugada challenge test in V1 R-V3 R as a predictor of malignant prognosis in Brugada patients.

Authors:  Arash Hashemi; Shahab Shahrzad; Sorayya Shahrzad; Siamak Saber; Samira Taban; Amir Aslani; Zahra Emkanjoo
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

Review 4.  Brugada syndrome: current clinical aspects and risk stratification.

Authors:  Takanori Ikeda
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-07       Impact factor: 1.468

Review 5.  Brugada syndrome: recent advances and controversies.

Authors:  Charles Antzelevitch; Eyal Nof
Journal:  Curr Cardiol Rep       Date:  2008-09       Impact factor: 2.931

6.  T-wave alternans and arrhythmogenesis in cardiac diseases.

Authors:  Zhilin Qu; Yuanfang Xie; Alan Garfinkel; James N Weiss
Journal:  Front Physiol       Date:  2010-11-29       Impact factor: 4.566

7.  T wave alternans and ventricular tachyarrhythmia risk stratification: a review.

Authors:  Masahiko Takagi; Junichi Yoshikawa
Journal:  Indian Pacing Electrophysiol J       Date:  2003-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.